VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Venetoclax plus azacitidine in treatment-naïve and R/R MDS

Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, discusses the results of two Phase Ib dose-escalation trials (NCT02942290; NCT02966782) of combined venetoclax and azacitidine, in treatment-naïve high-risk myelodysplastic syndrome (MDS) and relapsed/refractory (R/R) high-risk MDS, respectively. Venetoclax, a BCL-2 inhibitor, has shown synergy with hypomethylating agents in preclinical studies of MDS. The trial in treatment-naïve patients showed the combination to be tolerable and induce high response rates that were durable. Similarly, venetoclax and azacitidine produced encouraging rates of complete remission in relapsed/refractory patients and had a manageable safety profile. Both trials are ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Consulting fees: Boston Biomedical, PTC Therapeutics, Agios, Celgene/Bristol-Myers Squibb, Abbvie, Astellas, Novartis, Daiichi Sankyo, Trovagene, Seattle Genetics, Amgen, Pfizer, NewLink Genetics, Jazz, Takeda, Genentech, Blueprint, Kura Oncology, Kite, Amphivena, Trillium, Forty Seven/Gilead

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter